STAT3 cyclic oligonucleotide decoy—a new therapeutic avenue for NSCLC?

Lung cancer is still the main cause of cancer-related death and accounts for nearly 1.8 million deaths worldwide every year (1,2). About 85–90% of patients with lung cancer have non-small cell lung cancer (NSCLC) with most presenting with advanced metastatic disease. Despite the introduction of immune check-point inhibitors (IO) and newer generation of more effective EGFR TKIs and ALK inhibitors recently, there is still an unmet clinical need for improved treatment options for both wild-type and oncogenic-addicted NSCLC as most of these treated patients still develop disease resistance. Novel treatment strategies including identifying new treatment targets are still needed to improve outcome.